Stock Ratings / Health Care / APVO / financials

SILO (19) SBFM (44) PRFX (39) HCWB (27) ⌘ Pro Terminal →

Aptevo Therapeutics Inc. (APVO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.36 (+4.62% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APVO ranks #465 in composite RQD confidence.

Q: How does APVO compare to SILO and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SILO (Silo Pharma Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for APVO?

Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $0 in revenue, -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is APVO trading relative to its 50-day, 200-day, and 52-week technical levels?

APVO last traded at $1.36 (+4.62% on volume of 58,518 shares), positioning the stock -26.49% below its 50-day simple moving average ($1.85) and -68.88% below its 200-day simple moving average ($4.37). Across its 52-week range of $1.25 to $28.08, APVO sits at the 0.4% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).

Q: How profitable is Aptevo Therapeutics Inc. (APVO)?

In FY 2025 (10-K), APVO converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.36 +4.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.37

Aptevo Therapeutics Inc. (APVO) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.37 (+0.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APVO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY APVO SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.9 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.79-9.5% Next Q

Q2 (-2Q)

Grade C-$1.62-0.6% Next Q

Q3 (-1Q)

Grade D$1.61-15.5% Next Q

Current

Grade D$1.36-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APVO currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.43) forces dealer call-delta covering toward $29.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APVO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How APVO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.7%	-$26.0M	-$25.6M	-45%
FY 2024	$4.00B	52%	-0.6%	-$24.1M	-$23.8M	-45%
FY 2023	$4.00B	52%	-0.7%	-$17.4M	-$11.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APVO)

✓Walkthrough of APVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.36H $1.39L $1.31C $1.36VOL 28.7K

RES: $3.49SUP: $1.24SMA50: $1.85SMA200: $4.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APVO Butterfly Map → + Track APVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APVO)

Health Care Rank #465 of 1016 ⚔️ SILO vs APVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APVO vs. SILO, SBFM, PRFX, HCWB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aptevo Therapeutics Inc. (APVO) ranks #465 by composite RQD confidence (46/100, grade D) and #989 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, APVO leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APVO ACTIVE Aptevo Therapeutics Inc.	D	46/100	—	—	-35.0%	+4.62%	$2.5M	Benchmark Subject
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-apvo →
SBFM Sunshine Biopharma Inc.	D	44/100	—	33.8%	-21.4%	+7.07%	$2.5M	/sbfm-vs-apvo →
PRFX PRF Technologies Ltd.	D-	39/100	—	-30.0%	-35.0%	-3.86%	$2.6M	/prfx-vs-apvo →
HCWB HCW Biologics Inc.	E	27/100	—	20.0%	-35.0%	-3.28%	$2.6M	/hcwb-vs-apvo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671584

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aptevo Therapeutics Inc. (APVO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.0M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-7.6% YoY). On the balance sheet, APVO closed FY2025 with $27.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.0M	-$25.6M	-$25.6M	$27.2M	—
FY2024 (FY)	2024-12-31	$0	-$24.1M	-$23.8M	-$23.8M	$15.6M	—
FY2023 (FY)	2023-12-31	$0	-$17.4M	-$11.7M	-$11.7M	—	—

3. APVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.36 (+4.62% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APVO ranks #465 in composite RQD confidence.

How does APVO compare to SILO and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SILO (Silo Pharma Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APVO?

Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $0 in revenue, -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APVO trading relative to its 50-day, 200-day, and 52-week technical levels?

APVO last traded at $1.36 (+4.62% on volume of 58,518 shares), positioning the stock -26.49% below its 50-day simple moving average ($1.85) and -68.88% below its 200-day simple moving average ($4.37). Across its 52-week range of $1.25 to $28.08, APVO sits at the 0.4% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).

APVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Aptevo Therapeutics Inc. (APVO)?

In FY 2025 (10-K), APVO converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: APVO RQD Cockpit APVO 12M Forecast APVO Earnings & Move APVO Dividends & DRIP APVO Insiders & 13F APVO Whale Options APVO Profit Sankey APVO News & Why